FDA Adcomm Votes Unanimously to Recommend Intercept’s Obeticholic Acid

Weighing the risks and benefits of Intercept Pharmaceuticals’ obeticholic acid, an FDA advisory committee voted unanimously 17-0 on the significance of alkaline phosphatase levels as evidence to justify an accelerated approval of the primary biliary cirrhosis candidate.
Source: Drug Industry Daily